Navigation Links
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
Date:3/21/2011

VPRIV Important Safety Information

The most serious adverse reactions seen with VPRIV were hypersensitivity reactions. Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, low or high blood pressure, nausea, tiredness and weakness, and fever.  Generally the infusion-related reactions were mild and, in treatment-naïve patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.  

All adult side effects of VPRIV are considered relevant to children (ages 4 to 17 years). Side effects more commonly seen in children compared with adult patients included: upper respiratory tract infection, rash, aPTT prolonged, and fever. The safety of VPRIV has not been established in patients younger than 4 years of age.

As with all therapeutic proteins, there is a potential for immunogenicity. In the clinical studies 1 of 54 treatment-naïve patients treated with VPRIV developed IgG class antibodies.  It is unknown if the presence of IgG antibodies to VPRIV is associated with a higher risk of infusion reactions. 

VPRIV is not available in all countries and prescribing information may differ between countries.  Please consult your local prescribing information.  Full prescribing information for VPRIV in the US can be found at www.VPRIV.com.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
2. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
3. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
4. Reportlinker Adds Shire plc: PharmaVitae Profile
5. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
6. Shire plc - Statement re ProAmatine
7. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
10. Shire plc Appoints Two New Board Directors
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 According to a ... Dots Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 88.5 million in 2011, which is ... at a CAGR of 53.8% from 2013 to 2023. ... at  http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand for energy ...
(Date:7/31/2014)... -- Research and Markets has announced the ... report to their offering. ... the genetic material or genomes of an organism. It ... discovery and development of diagnostic and therapeutic solutions for ... is supported by three major product segments: Instruments, Consumables, ...
(Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
(Date:7/31/2014)... BOTHELL, Wash. , July 31, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s second quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Biology Technology:Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2
... Gyeonggi Province, ST. LOUIS, Nov. 5 SAFC ... Sigma-Aldrich Group (Nasdaq: SIAL ),today announced that a ... Korea has been signed. The MoU signals the Company,s,intentions ... being built in the province for the supply and ...
... of second line HRPC patients on TPI 287 show clinical ... TPPH ) announced today financial results for,the third quarter ... third quarter of 2007 was $6.1 million, or $0.37,per share. ... of 2006 of,$3.6 million, or $0.22 per share. Included in ...
... 4 Scientists at Monsanto,Company working in collaboration ... approach to protect crops against insects, which,models a ... The,technology is expected to provide farmers with a ... another tool to support agriculture,s,mission of meeting the ...
Cached Biology Technology:SAFC Hitech(TM) Plans Further Expansion Into Asia 2SAFC Hitech(TM) Plans Further Expansion Into Asia 3Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 2Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 3Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 4Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 5Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 6Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial 7Monsanto and Devgen Describe New Approach to Insect-Protection 2Monsanto and Devgen Describe New Approach to Insect-Protection 3
(Date:7/31/2014)... studies have shown that marine noise can affect animal ... the Universities of Bristol and Exeter and the cole ... demonstrated that boat noise stops embryonic development and increases ... the sea slug Stylocheilus striatus used in ... away and later feed on toxic alga but this ...
(Date:7/30/2014)... A deep-sea octopus protected and tended her eggs until ... published July 30, 2014 in the open-access journal ... Aquarium Research Institute and colleagues. , Octopuses typically have ... females protect and take care of their fertilized eggs ... eggs for 1 to 3 months, but little is ...
(Date:7/30/2014)... University of Helsinki and the Universitat Autnoma de Barcelona ... changes which have taken millions of years to occur. ... of mice teeth, induced in the laboratory, scientists have ... observed in the fossil registry of rodent species which ... To modify the development of their teeth, the team ...
Breaking Biology News(10 mins):Boat noise impacts development and survival of sea hares 2Deep-sea octopus has longest-known egg-brooding period 2Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... - Everyone is special in their own unique way. From ... identical. This means that DNA for each individual contains variants ... population. Some gene variations are actually genetic deletions, ... are likely to have important effects on gene function and, ...
... has often been associated with improving people,s health, but a ... hormones in a way that reduces stress. Unmarried people ... to stress as do married people, said Dario Maestripieri, Professor ... lead author of the study, published in the current issue ...
... has proved effective in preventing fouling of ship bottoms. Researchers ... that causes the barnacle to react to the substance, opening ... both on barnacles and on the environment. Fouling of ... leisure craft as well as large cargo ships. The University ...
Cached Biology News:Developmental problems: Some exist in the genes 2Marriage and committed romance reduce stress-related hormone production 2Gene that causes barnacles to avoid ship hulls identified 2